Search

Your search keyword '"Matsuda, Mitsuhiro"' showing total 700 results

Search Constraints

Start Over You searched for: Author "Matsuda, Mitsuhiro" Remove constraint Author: "Matsuda, Mitsuhiro"
700 results on '"Matsuda, Mitsuhiro"'

Search Results

1. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

2. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

3. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

4. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum

6. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

10. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial

11. Metabolic activities are selective modulators for individual segmentation clock processes.

12. Hybridized microstructures of oxygen‐defective HfO2−x films produced by controlling oxidation of metallic Hf foil.

13. Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia

19. Low absolute lymphocyte count is a poor prognostic factor for untreated advanced follicular lymphoma treated with rituximab plus bendamustine: results of the prospective phase 2 CONVERT trial

22. Recapitulating the human segmentation clock with pluripotent stem cells

24. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

26. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)

27. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum

28. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

29. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

30. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

31. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

36. A stem cell zoo uncovers intracellular scaling of developmental tempo across mammals

45. This title is unavailable for guests, please login to see more information.

46. Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis

49. Novel prognostic predictor of haemoglobin–platelet index in diffuse large B‐cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL ‐6 production in lymphoma cells

50. sj-docx-14-tah-10.1177_20406207221142487 – Supplemental material for Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide

Catalog

Books, media, physical & digital resources